Search

New heterocyclic compound (S)-3-(4-(5-bromo-2-chlorobenzyl)phenoxy)tetrahydrofuran (1), designed by utilizing 5-bromo-2-chlorobenzoic acid (2) as the starting material, is obtained by the organic synthesis and then characterized by single crystal X-ray crystallography, 1H NMR and IR spectroscopy. In the biological study, the CCK-8 assay is performed to evaluate the inhibitory effect of the compound on SPC-A-1 human lung adenocarcinoma cells in vitro by measuring the cancer cell viability. Then, the anticancer activity of the compound is also confirmed by the in vivo xenograft experiment by measuring the mice body weight and the cancer volume. [ABSTRACT FROM AUTHOR]

Heterocyclic compound 1-((2S,3S)-2-(benzyloxy)pentan-3-yl)-4-(4-(4-(4-hydroxyphenyl)piperazin-1-yl)phenyl)-1H-1,2,4-triazol-5(4H)-one (1) designed using 4-(4-(4-aminophenyl)piperazin-1-yl)phenol (2) and (S)-N′-(2-(benzyloxy)propylidene)formohydrazide (3) as start materials is successfully obtained via a multistep synthesis and finally characterized by IR, 1H NMR, and single crystal X-ray diffraction. In addition, the in vitro anticancer activities of newly synthesized compound 1 are evaluated against three human bone cancer cell lines U2OS, Saos-2, and GC9811. In addition, the molecular docking is used to study the potential antiviral activity of 1 by calculating the binding sites for the 1AS0 protein. [ABSTRACT FROM AUTHOR]